ONC vs. RGC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ONC and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
ONC trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, RGC is a standard domestic listing.
| Symbol | ONC | RGC |
|---|---|---|
| Company Name | BeOne Medicines Ltd. | Regencell Bioscience Holdings Limited |
| Country | Switzerland | Hong Kong |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 38.13 billion USD | 6.10 billion USD |
| Exchange | NasdaqGS | NasdaqCM |
| Listing Date | February 3, 2016 | July 16, 2021 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of ONC and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ONC | RGC |
|---|---|---|
| 5-Day Price Return | 0.39% | -7.08% |
| 13-Week Price Return | -3.98% | 20.60% |
| 26-Week Price Return | 22.74% | 12,370.00% |
| 52-Week Price Return | 20.61% | 5,568.18% |
| Month-to-Date Return | -1.49% | -5.53% |
| Year-to-Date Return | 45.76% | 9,492.31% |
| 10-Day Avg. Volume | 3.70M | 0.26M |
| 3-Month Avg. Volume | 2.80M | 2.29M |
| 3-Month Volatility | 45.83% | 644.75% |
| Beta | 0.62 | 2.37 |
Profitability
Return on Equity (TTM)
ONC
-12.94%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
ONC has a negative Return on Equity of -12.94%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
RGC
-54.75%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
ONC
-10.58%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
ONC has a negative Net Profit Margin of -10.58%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
RGC
--
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
Net Profit Margin data for RGC is currently unavailable.
Operating Profit Margin (TTM)
ONC
-7.30%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
ONC has a negative Operating Profit Margin of -7.30%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
RGC
--
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
Operating Profit Margin data for RGC is currently unavailable.
Profitability at a Glance
| Symbol | ONC | RGC |
|---|---|---|
| Return on Equity (TTM) | -12.94% | -54.75% |
| Return on Assets (TTM) | -7.59% | -51.38% |
| Net Profit Margin (TTM) | -10.58% | -- |
| Operating Profit Margin (TTM) | -7.30% | -- |
| Gross Profit Margin (TTM) | 84.66% | -- |
Financial Strength
Current Ratio (MRQ)
ONC
1.95
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
ONC’s Current Ratio of 1.95 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
RGC
42.68
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio (MRQ)
ONC
0.32
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
ONC’s Debt-to-Equity Ratio of 0.32 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RGC
0.00
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
ONC
-132.16
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
ONC has a negative Interest Coverage Ratio of -132.16. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
RGC
--
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
Interest Coverage Ratio data for RGC is currently unavailable.
Financial Strength at a Glance
| Symbol | ONC | RGC |
|---|---|---|
| Current Ratio (MRQ) | 1.95 | 42.68 |
| Quick Ratio (MRQ) | 1.66 | 41.89 |
| Debt-to-Equity Ratio (MRQ) | 0.32 | 0.00 |
| Interest Coverage Ratio (TTM) | -132.16 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ONC
0.16%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC’s Dividend Yield of 0.16% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ONC
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ONC | RGC |
|---|---|---|
| Dividend Yield (TTM) | 0.16% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ONC
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for ONC is currently unavailable.
RGC
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for RGC is currently unavailable.
Price-to-Sales Ratio (TTM)
ONC
9.24
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
ONC’s P/S Ratio of 9.24 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RGC
--
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
P/S Ratio data for RGC is currently unavailable.
Price-to-Book Ratio (MRQ)
ONC
8.99
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
ONC’s P/B Ratio of 8.99 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
RGC
9.57
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | ONC | RGC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | -- |
| Price-to-Sales Ratio (TTM) | 9.24 | -- |
| Price-to-Book Ratio (MRQ) | 8.99 | 9.57 |
| Price-to-Free Cash Flow Ratio (TTM) | -- | -- |